CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
A new partnership between the Marathon of Hope Cancer Centres Network (MOHCCN) and the Canadian Clinical Trials Group (CCTG) will support three pan-Canadian research teams
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Conventional Radiotherapy in Patients with Advanced Head and Neck Cancer
The GA1 TOPGEAR trial results were presented at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain and simultaneously published in the New England Journal of Medicine.
TOPGEAR researchers investigated adding concurrent radiotherapy to standard treatment to determine if it would improve pathological complete response rates and ultimately overall survival of these patients with resectable gastric and gastro-esophageal junction adenocarcinoma. The study found that there was no significant benefit of chemoradiotherapy on long term survival which was the main aim of the trial. The survival rate at 5 years was about 45% in both groups. As a result, it is recommended that chemoradiotherapy not become a routine standard of care.
“We now know that with high quality surgery and perioperative chemotherapy, preoperative CRT should not be used in management of patients with resectable gastric cancer,” says Dr. Rebecca Wong, Canadian study chair and Professor, University of Toronto; Director, Education, Radiation Medicine, Princess Margaret Cancer Center, UHN. “The doubling of pathological complete response rates and the absence of incremental moderate to severe toxicities when CRT was used provide important data to guide the future exploration of radiotherapy in the management of gastric cancers.”
The Journal of Clinical Oncology has published ‘Correlative Science in the Cooperative Group System—Re-Engineering for Success,’ which proposes public-private partnerships to increase resources and process innovations to open access to tissue banks
Late breaking results of the Canadian Cancer Trials Group (CCTG) BR31 study “A double-blind, placebo-controlled, randomized phase 3 trial of adjuvant durvalumab in completely resected non-small-cell lung cancer” were presented at the European Society for Medical Oncology (ESMO) Congress 2024.
CCTG MAC29 is investigating whether treatment with immunotherapy versus observation in people with early-stage triple-negative breast cancer (TNBC) who had a good response after initial treatment with chemotherapy and immunotherapy is really necessary.
ME17 one of the world’s largest randomized controlled clinical trials using fecal microbiota transplantation (FMT) to improve the effectiveness of the standard of care for advanced melanoma.
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS
Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade Compared to Immune Checkpoint Blockade Alone in Patients with Advanced Melanoma
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated with Immuno-Oncotherapeutics (CAN-IMPACT-IO)
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes
TRIPLE-SWITCH: Docetaxel to Androgen Receptor Pathway Inhibitors in Metastatic Castration Sensitive Prostate Cancer Without Deep PSA Response
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)
Doxorubicin + Pembrolizumab vs Doxorubicin for Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score = 25 (OFSET)
STOPNET - Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Tumours
Stereotactic Body Radiotherapy (SBRT) vs Conventional Palliative Radiotherapy (CRT) for Participants with Painful Non-Spine Bone Metastases
Please join the Patient Representative Committee in welcoming Michelle Audoin who will be supporting the Breast Disease Site committee.
CCTG would like to welcome our new Patient Representative Haydn Bechthold who will be supporting the Gastrointestinal Disease Site Committee.
A very warm welcome to Jasmine Heuring who has joined the CCTG Patient Representatives Committee and will be supporting the Adolescents & Young Adults and Sarcoma Disease Site Committees. Jasmine is from Winnipeg Manitoba and is a cancer advocate and healthcare analyst.
Translational Lung Cancer Research 10: 826 - 838, 21 FFung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;
N Engl J Med 388: 2159 - 2170, 2023Eskander RN;Sill MW;Beffa L;Moore RG;Hope JM;Musa FB;Mannel R;Shahin MS;Cantuaria GH;Girda E;Mathews C;Kavecansky J;Leath CA;Gien LT;Hinchcliff EM;Lele SB;Landrum LM;Backes F;O'Cearbhaill RE;Al Baghdadi T;Hill EK;Thaker PH;John VS;Welch S;Fader AN;Powell MA;Aghajanian C;
International Journal of Radiation Oncology*Biology*Physics , 2023Petersen PM;Cook AD;Sydes MR;Clarke N;Cross W;Kynaston H;Logue J;Neville P;Payne H;Parmar MKB;Parulekar W;Persad R;Saad F;Stirling A;Parker CC;Catton C;
The Oncol , 2023Gupta A;Hay AE;Crump M;Djurfeldt MS;Zhu L;Cheung MC;Shepherd LE;Chen BE;Booth CM;
N Engl J Med 388: 1645 - 1656, 2023Partridge AH;Niman SM;Ruggeri M;Peccatori FA;Azim HA;Colleoni M;Saura C;Shimizu C;Sætersdal AB;Kroep JR;Mailliez A;Warner E;Borges VF;Amant F;Gombos A;Kataoka A;Rousset-Jablonski C;Borstnar S;Takei J;Lee JE;Walshe JM;Ruíz-Borrego M;Moore HCF;Saunders C;Bjelic-Radisic V;Susnjar S;Cardoso F;Smith KL;Ferreiro T;Ribi K;Ruddy K;Kammler R;El-Abed S;Viale G;Piccart M;Korde LA;Goldhirsch A;Gelber RD;Pagani O;
J Thoracic Oncol 18: e68 - e69, 2023Piccirillo MC;Chu Q;Bradbury P;Seymour L;
Cancers 15: 1823, 2023Karamouza E;Glasspool RM;Kelly C;Lewsley LA;Carty K;Kristensen GB;Ethier JL;Kagimura T;Yanaihara N;Cecere SC;You B;Boere IA;Pujade-Lauraine E;Ray-Coquard I;Proust-Lima C;Paoletti X;
Supportive Care in Cancer 31: 256, 2023Mian H;Ringash J;Meyer R;Hay AE;Shepherd L;Djurfeldt M;Winter JN;Sussman J;Pater J;Chen BE;Prica A;